The history of the erectile dysfunction drug presents a intricate picture for shareholders. While the initial launch generated substantial returns, the expiration of its intellectual property protection opened the floodgates to cheaper competitors, dramatically reducing revenue. This creates a specific risk for pharmaceutical companies banking on c

The story of Viagra, and its developer copyright, presents a complex case study for investors. Initially a blockbuster drug, generating billions in revenue , its patent expiration created a flood of generic competition , significantly impacting its position . While specific businesses may attempt to capitalize on male sexual dysfunction, the existi